Does the media prefer SPRY or ADPT?

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 8 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Adaptive Biotechnologies' score of 0.15 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ALMS or SPRY?

ARS Pharmaceuticals has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 148.96 -$243.32M -$1.98 N/A ARS Pharmaceuticals $84.28M 9.12 -$171.30M -$2.01 N/A

Is ALMS or SPRY more profitable?

ARS Pharmaceuticals has a net margin of -200.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat ARS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% ARS Pharmaceuticals -200.00% -153.61% -60.85%

Does the media prefer ALMS or SPRY?

In the previous week, ARS Pharmaceuticals had 2 more articles in the media than Alumis. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 6 mentions for Alumis. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Alumis' score of 0.44 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SPRY or IDYA?

In the previous week, IDEAYA Biosciences had 1 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 8 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.51 beat IDEAYA Biosciences' score of 0.49 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GMTX or SPRY?

ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 264.34%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ARS Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer GMTX or SPRY?

In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 1 mentions for Gemini Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Gemini Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or SPRY?

In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 8 mentions for ARS Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat ARS Pharmaceuticals' score of 0.51 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ARS Pharmaceuticals (SPRY) Competitors

$7.74 -0.20 (-2.52%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$7.75 +0.01 (+0.09%)

As of 06:07 AM Eastern

Compare

SPRY vs. ADPT, ALMS, IDYA, GMTX, and RARE

Should you buy ARS Pharmaceuticals stock or one of its competitors? MarketBeat compares ARS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ARS Pharmaceuticals include Adaptive Biotechnologies (ADPT), Alumis (ALMS), IDEAYA Biosciences (IDYA), Gemini Therapeutics (GMTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.

How does ARS Pharmaceuticals compare to Adaptive Biotechnologies?

ARS Pharmaceuticals (NASDAQ:SPRY) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

ARS Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market.

Adaptive Biotechnologies has higher revenue and earnings than ARS Pharmaceuticals. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.12	-$171.30M	-$2.01	N/A
Adaptive Biotechnologies	$276.98M	12.15	-$59.50M	-$0.33	N/A

Adaptive Biotechnologies has a net margin of -16.82% compared to ARS Pharmaceuticals' net margin of -200.00%. Adaptive Biotechnologies' return on equity of -40.06% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 8 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Adaptive Biotechnologies' score of 0.15 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ARS Pharmaceuticals presently has a consensus price target of $28.20, indicating a potential upside of 264.34%. Adaptive Biotechnologies has a consensus price target of $20.83, indicating a potential downside of 0.89%. Given ARS Pharmaceuticals' higher possible upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Adaptive Biotechnologies beats ARS Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Alumis?

Alumis (NASDAQ:ALMS) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, ARS Pharmaceuticals had 2 more articles in the media than Alumis. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 6 mentions for Alumis. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Alumis' score of 0.44 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis has a beta of -0.73, suggesting that its stock price is 173% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

ARS Pharmaceuticals has a net margin of -200.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Alumis currently has a consensus target price of $40.30, indicating a potential upside of 43.42%. ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 264.34%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

68.2% of ARS Pharmaceuticals shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ARS Pharmaceuticals has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	148.96	-$243.32M	-$1.98	N/A
ARS Pharmaceuticals	$84.28M	9.12	-$171.30M	-$2.01	N/A

Summary

ARS Pharmaceuticals beats Alumis on 11 of the 17 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to IDEAYA Biosciences?

ARS Pharmaceuticals (NASDAQ:SPRY) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

IDEAYA Biosciences has higher revenue and earnings than ARS Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.12	-$171.30M	-$2.01	N/A
IDEAYA Biosciences	$218.71M	14.52	-$113.70M	-$1.60	N/A

In the previous week, IDEAYA Biosciences had 1 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 8 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.51 beat IDEAYA Biosciences' score of 0.49 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. IDEAYA Biosciences' return on equity of -14.24% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

ARS Pharmaceuticals presently has a consensus price target of $28.20, suggesting a potential upside of 264.34%. IDEAYA Biosciences has a consensus price target of $50.25, suggesting a potential upside of 39.00%. Given ARS Pharmaceuticals' higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ARS Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

Summary

IDEAYA Biosciences beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Gemini Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Gemini Therapeutics' return on equity of -38.78% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 264.34%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gemini Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Gemini Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
ARS Pharmaceuticals	$84.28M	9.12	-$171.30M	-$2.01	N/A

In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 1 mentions for Gemini Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.51 beat Gemini Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gemini Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Summary

ARS Pharmaceuticals beats Gemini Therapeutics on 9 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Ultragenyx Pharmaceutical currently has a consensus target price of $58.41, suggesting a potential upside of 75.83%. ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 264.34%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ARS Pharmaceuticals has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.86	-$575M	-$6.11	N/A
ARS Pharmaceuticals	$84.28M	9.12	-$171.30M	-$2.01	N/A

In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 8 mentions for ARS Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat ARS Pharmaceuticals' score of 0.51 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats ARS Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$788.47M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-3.85	19.17	27.11	24.26
Price / Sales	9.12	838.79	589.96	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	6.67	4.22	10.74	6.29
Net Income	-$171.30M	$64.26M	$3.58B	$330.66M
7 Day Performance	-5.49%	-3.58%	-2.11%	-1.35%
1 Month Performance	-20.70%	2.12%	3.27%	-0.64%
1 Year Performance	-56.76%	20.35%	26.31%	19.08%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	3.2556 of 5 stars	$7.74 -2.5%	$28.20 +264.3%	-56.2%	$788.47M	$84.28M	N/A	90
ADPT Adaptive Biotechnologies	1.7532 of 5 stars	$21.50 +1.5%	$20.50 -4.7%	+77.8%	$3.39B	$276.98M	N/A	790
ALMS Alumis	3.1091 of 5 stars	$27.27 +2.9%	$40.30 +47.8%	+698.3%	$3.38B	$24.05M	N/A	N/A
IDYA IDEAYA Biosciences	3.4862 of 5 stars	$39.37 +4.6%	$50.69 +28.7%	+60.8%	$3.31B	$218.71M	N/A	80
GMTX Gemini Therapeutics	N/A	$76.26 +1.7%	N/A	+34.6%	$3.30B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. ADPT, ALMS, IDYA, GMTX, and RARE

How does ARS Pharmaceuticals compare to Adaptive Biotechnologies?

Summary

How does ARS Pharmaceuticals compare to Alumis?

Summary

How does ARS Pharmaceuticals compare to IDEAYA Biosciences?

Summary

How does ARS Pharmaceuticals compare to Gemini Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. ADPT, ALMS, IDYA, GMTX, and RARE

How does ARS Pharmaceuticals compare to Adaptive Biotechnologies?

Which has more risk & volatility, SPRY or ADPT?

Which has preferable earnings and valuation, SPRY or ADPT?

Is SPRY or ADPT more profitable?

Does the media prefer SPRY or ADPT?

Do institutionals and insiders believe in SPRY or ADPT?

Do analysts prefer SPRY or ADPT?

Summary

How does ARS Pharmaceuticals compare to Alumis?

Does the media prefer ALMS or SPRY?

Which has more risk & volatility, ALMS or SPRY?

Is ALMS or SPRY more profitable?

Do analysts rate ALMS or SPRY?

Do institutionals & insiders believe in ALMS or SPRY?

Which has stronger earnings and valuation, ALMS or SPRY?

Summary

How does ARS Pharmaceuticals compare to IDEAYA Biosciences?

Which has stronger valuation and earnings, SPRY or IDYA?

Does the media favor SPRY or IDYA?

Is SPRY or IDYA more profitable?

Do analysts recommend SPRY or IDYA?

Do institutionals and insiders hold more shares of SPRY or IDYA?

Which has more volatility & risk, SPRY or IDYA?

Summary

How does ARS Pharmaceuticals compare to Gemini Therapeutics?

Is GMTX or SPRY more profitable?

Do analysts rate GMTX or SPRY?

Do institutionals & insiders have more ownership in GMTX or SPRY?

Which has higher valuation & earnings, GMTX or SPRY?

Does the media prefer GMTX or SPRY?

Which has more volatility & risk, GMTX or SPRY?

Summary

How does ARS Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Which has more risk and volatility, RARE or SPRY?

Is RARE or SPRY more profitable?

Do analysts rate RARE or SPRY?

Which has preferable earnings & valuation, RARE or SPRY?

Does the media refer more to RARE or SPRY?

Do insiders & institutionals hold more shares of RARE or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools